On May 25, 2017 at 12:00 p.m. ET, NCI will host a Facebook Live event about Advanced Melanoma Research and Treatment. Subject matter experts from NCI and the University of Chicago will discuss research and treatment for advanced stage melanoma with advocate Jamie Troil-Goldfarb, a clinical trial participant and stage IV melanoma survivor.
A new study conducted in collaboration with a cooperative group chemoradiotherapy clinical trial finds that most patients participating in the multicenter trial were willing and able to self report symptomatic adverse events using NCI’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy to treat patients with cancer that has spread to the brain.
This phase I trial studies the side effects of a therapeutic vaccine combined with nivolumab with or without ipilimumab in treating men with prostate cancer.
This pilot phase II trial studies tocilizumab in treating patients with Kaposi sarcoma herpes virus (KSHV)-associated multicentric Castleman disease, a type of lymphoproliferative disease similar to lymphoma.
